Entrada Therapeutics

Entrada Therapeutics is a biotechnology company focused on developing novel therapeutics for the treatment of rare and devastating diseases. They leverage their proprietary Endosomal Escape Vehicle (EEV) technology to deliver biologics and nucleic acids directly into the cytosol of target cells, addressing previously undruggable intracellular targets. Founded in 2016, Entrada has made significant strides in advancing their pipeline, with a particular emphasis on neuromuscular and immunological disorders. Their revenue model primarily involves research and development partnerships, grants, and potential future product sales.

Recent Posts by Entrada Therapeutics

1-9 of 9